# Energy‐Based Devices for the Treatment of Cutaneous Lesions in Patients With Lupus Erythematosus and Dermatomyositis

## TL;DR

This study shows that energy-based devices can safely improve skin conditions in patients with lupus and dermatomyositis.

## Contribution

The study provides real-world evidence of the safety and efficacy of energy-based devices in autoimmune skin conditions.

## Key findings

- Patients showed significant improvement in erythema, dyspigmentation, and skin morphology.
- Treatments were well-tolerated with only transient side effects and no disease reactivation.
- Some lupus patients exhibited enhanced follicular activity after treatment.

## Abstract

The use of energy‐based devices (EBDs) for aesthetic and dermatological conditions is increasing, but data on efficacy and safety in autoimmune connective tissue disease (CTD) patients remain limited.

This study assesses EBD real‐world treatment outcomes in Korean patients with lupus erythematosus (LE) and dermatomyositis (DM).

A retrospective, uncontrolled study was conducted on 26 CTD patients (LE: 20, DM: 6) treated at Hanyang University Seoul Hospital (2015–2023). Various laser modalities, including pulsed‐dye laser (PDL), intense pulsed light (IPL), long‐pulse Nd:YAG (LPNY), Q‐switched Nd:YAG (QSNY), and ablative fractional laser (AFL), were analyzed. Two independent dermatologists evaluated treatment outcomes using a 5‐point modified Investigator's Global Assessment (IGA) scale.

Patients showed significant improvement in erythema, dyspigmentation, and overall skin morphology. Some LE patients also exhibited enhanced follicular activity. Treatments were well‐tolerated, with only transient side effects reported, and no long‐term complications or disease reactivation occurred.

EBD treatments may provide cosmetic improvement in selected LE and DM patients and are generally safe. Larger controlled studies are needed to confirm efficacy and establish optimal protocols.